CG Oncology's experimental drug cretositimogene grenadenorepvec (cret) for non-muscle invasive bladder cancer (NMIBC) demonstrated a 75% complete response rate at any time, with 46% at 12 months and 42% at 24 months in recent trials. The drug also showed a best-in-class safety profile with no severe (Grade 3 or higher) adverse events reported. The company plans to complete a rolling Biologics License Application (BLA) by the fourth quarter of 2026, with multiple clinical trial results expected in the second half of 2026 and 2027. This progress has driven CG Oncology's shares up over 150% in the past year, reflecting strong investor confidence in the drug's potential.
AtlasClear Holdings announced stock option awards for its executive leaders and board members to support long-term retention and align interests with shareholders. The options, granted on October 1, 2026, allow purchase of shares at $0.2010 each and ...
Valor Gold Corp. announced the sudden illness and passing of its CEO, Mark Ashley, a respected leader and mentor. Alan Edwards, the Chairman, will serve as interim CEO, ensuring leadership continuity as the company advances its gold exploration proje...
Hilton Grand Vacations (HGV) has been upgraded to a 'strong buy' with a price target of $55, indicating over 50% potential upside. Despite recent stock declines and weak vacation ownership interest (VOI) sales, HGV's stable recurring revenue and impr...
Cardano's ADA surged 10% in 24 hours to over 27 cents, its highest level since May, outperforming Bitcoin and Ether which rose modestly. The rally is likely driven by excitement around Cardano's new RealFi institutional credit product offering up to ...
Banka has integrated Bitcoin trading into its mobile app, allowing customers to buy and sell BTC directly through their bank accounts without opening a separate exchange account. Users can start trading with as little as 500 koruna (about $23) and tr...
